Sentence examples for main effector cells from inspiring English sources

It is well known that neutrophils are the main effector cells of the immune response contributing to bacterial clearance during a UTI42.

Given that activated PSCs are the main effector cells in pancreatic fibrosis, targeting PSCs can offer a novel therapeutic approach to normalise the tumour stroma.

Human leukocyte antigen (HLA -G displays immunotolerogenic properties toward tHLA -Gn effector cells involvedisplaysft rejectimmunotolerogenicition of natural killer cell- and cytotoxic T-lympropertiesdiatowardtheysis, and CD4 T-cell alloproliferation.

The levels of ELR+ CXC chemokines are elevated in the joints of this arthritic mice and neutrophils, which have upregulated CXCR2 in the joint, are the main effector cells, making the K/BxN serum transfer-induced arthritis mice a valid model to test the therapeutic efficacy of our engineered binders13,14,37,38.

CD8+ T cells are the main effector cells responsible for viral clearance as well as disease pathogenesis during HBV infection (Thimme et al., 2003; Harari et al., 2006; Ouyang et al., 2013).

Whereas CTLs are traditionally thought to be the main effector cells that eliminate HCV-infected cells [5], it is clear that HCV-specific CD4+ T cells also play a critical role.

CD8+ cytotoxic lymphocytes (CTLs) are known to be the main effector cell in viral infection [ 6].

Thus, the myofibroblast is widely considered the main effector cell of fibrosis and thereby a major therapeutic target.

FLS is a main effector cell type in the progression of RA, promoting pannus formation with cartilage erosion and progressive joint destruction by secreting diverse cytokines, chemokines, and MMPs [ 5, 8, 9].

We observed no expression enrichment of CeD genes in any of the cell types tested, suggesting that the main effector cell type involved in the pathophysiology of CeD might not have been represented by the cell types present in our panel of cells.

B16FasL were selected for the following reasons: i) B16FasL, as opposed to B16F10, is rejected in RAG /– mice as efficiently as in B6 mice; ii) the innate immune response to B16FasL is sufficient to reject the tumour (Fig. 1); iii) we have identified NK cells as the main effector cell type mediating this innate B16FasL immunity in both B6 and RAG /– mice.